

AMENDMENTS TO THE SPECIFICATION

Please amend the specification bridging pages 22-23, paragraph [0064] as follows:

[0064] The cationic peptide immunogen comprises a Th epitope and a target B-cell epitope. The Th epitope may be intrinsic to the peptide or may be synthetically added to a peptide, which functions as a target B-cell epitope. Suitable peptide immunogens include peptides that elicit protective or therapeutic immune responses and are derived from pathogens or proteins known to cause diseases. These include: human or animal IgE peptides for the immunotherapy of allergies, e.g., the IgE peptide immunogens described in WO 99/67293⁵¹; HIV peptides for protective immunity and immunotherapy for HIV infection described in US 5,763,160⁵²; CD4 peptides for protective immunity from HIV and immunotherapy of HIV infection and immune disorders described in US 6,090,388⁵³; Luteinizing Hormone Releasing Hormone (LHRH) peptides for immunotherapy of androgen and estrogen-dependent tumors, contraception and immunocastration, and removal of boar taint described in ~~US 5,749,551~~US 5,759,551⁵⁴ and US 6,025,468⁵⁵; β -amyloid peptides for prevention and immunotherapy of Alzheimer's Disease described in USSN 09/865,294⁵⁶; foot-and-mouth disease virus peptides for protective immunity against foot-and-mouth disease described in US 6,107,021⁵⁷; peptides from bacterial pili for protective immunity from urinary tract infection described in US Application No. 09/747802⁵⁸; *Plasmodium* peptides for protective immunity from malaria described in WO 99/66957⁵⁹; and somatostatin peptides for growth promotion in livestock described in WO 99/66950.⁶⁰ The specific peptide immunogens named herein are examples for purposes of illustration only and are not to be construed as limiting the scope of the invention in any manner.